Atopic dermatitis (AD) is a common inflammatory skin disease with recurring episodes of itching and a chronic relapsing course. The prevalence of AD has increased exponentially over the years, along with information on how it may occur. Diagnosis of AD is typically based on physical examination and history and may be confirmed based on chronicity of symptoms, itching, and age-specific morphology. Nonpharmacological approaches include psychological interventions such as behavior modification, stress reduction techniques, and group psychotherapeutic treatments or may also include dietary restrictions, ultraviolet (UV) phototherapy, house dust mite reduction, and avoidance of enzyme-enriched detergents. Herbal therapy has also showed some promise particularly Zemaphyte®, Kamillosan®, and Shiunko®. Pharmacological agents that show great efficacy include emollients, topical corticosteroids, and topical calcineurin inhibitors.
LevyRMGelfandJMYanAC. The epidemiology of atopic dermatitis. Clin Dermatol. 2003;21(2):109–115.
2.
BeiberT. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–1494.
3.
HanifenJMRajkaG. Diagnostic feature of atopic dermatitis. Acta Derm Venereol. 1980;92:(suppl):44–47.
4.
KangKStevensS. Pathophysiology of atopic dermatitis. Clin Dermatol. 2003;21(2):116–121.
5.
KangKFTianRM. Atopic dermatitis. An evaluation of clinical and laboratory findings. Int J Dermatol. 1987;26(1):27–32.
6.
LipozenencicJWolfR. Atopic dermatitis: an update and review of the literature. Dermatol Clin. 2007;25(4):605–612.
7.
RosenFGehaR.
Case Studies in Immunology.New York, NY: Garland Publishing; 2004.
8.
AkdisCAAkdisMBieberT. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology; Clinical Immunology, Asthma and Immunology/PRACTICALL Consensus Report. Allergy. 2006;61(1):969–987.
9.
OngPYBoguniewicsM. Atopic dermatitis. Prim Care. 2008;35(1):105–117.
10.
WilliamsHC: Clinical practice. Atopic dermatitis. N Engl J Med. 2005;352(22):2314–2324.
11.
WesslerIReinheimerTKilbingerH. Increased acetylcholine levels in skin biopsies of patients with atopic dermatitis. Life Sci. 2003;72(18-19):2169–2172.
12.
SampsonHA. Update on food allergy. J Allergy Clin Immunol. 2004;113(5):805–819.
13.
WilliamsHC. Diagnostic criteria for atopic dermatitis (letter). Lancet. 1996;348(1):1391–1392.
14.
WilliamsHC. On the definition and epidemiology of atopic dermatitis. Dermatol Clin. 1995;13(3):649–657.
15.
WilliamsHCForsdykeHBoodooG. A protocol for recording the sign of flexural dermatitis in children. Br J Dermatol. 1995;133(6):941–949.
16.
HalbertAR. The practical management of atopic dermatitis in children. Pediatr Ann. 1996;25(2):72–78.
17.
Bindslev-JensenCBallmer-WeberBBengtssonU. Standardization of food challenges in patients with immediate reactions to foods—position paper from the European Academy of Allergology and Clinical Immunology. Allergy. 2004;59(7):690–697.
18.
ScalabrinDBavbekSPerzanowskiM. Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: a comparison with asthmatic and nonasthmatic control subjects. J Allergy Clin Immunol. 1999;104(6):1273–1279.
19.
WerfelTBreuerK. Role of food allergy in atopic dermatitis. Curr Opin Allergy Clin Immunol. 2004;4(5):379–385.
20.
DarsowULaifaouiJKerschenlohrK. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study. Allergy. 2004;59(12):1318–1325.
21.
LeungDY. Infection in atopic dermatitis. Curr Opin Pediatr. 2003;15(4):399–404.
HanifinJMCooperKDHoVC. Guidelines for atopic dermatitis. J Am Acad Dermatol. 2004;50(3):391–404.
24.
StaughtonR. Psychologic approach to atopic skin disease. J Am Acad Dermatol. 2001;45(1 suppl):S53–S54.
25.
EhlersAStangierUGielerU. Treatment of atopic dermatitis: a comparison of psychological and dermatological approaches to relapse prevention. J Consult Clin Psychol. 1995;63(4):624–635.
26.
SloperKSWadsworthJBrostoffJ. Children with atopic eczema. I: Clinical response to food elimination and subsequent double-blind food challenge. Q J Med. 1991;80(292):677–693.
27.
WilliamsHC. Atopic dermatitis. N Engl J Med. 2005;352(22):2314–2324.
28.
KrutmannJDiepgenTLLugerTA. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol. 1998;38(4):589–593.
29.
RicciGPatriziASpecchiaF. Effect of house dust mite avoidance measures in children with atopic dermatitis. Br J Dermatol. 2000;143(2):379–384.
30.
GutgesellCHeiseSSeubertS. Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis. Br J Dermatol. 2001;145(1):70–74.
31.
SandaTYasueTOohashiM. Effectiveness of house dust-mite allergen avoidance through clean room therapy in patients with atopic dermatitis. J Allergy Clin Immunol. 1992;89(3):653–657.
32.
AndersenPHBindslev-JensenCMosbechH. Skin symptoms in patients with atopic dermatitis using enzyme-containing detergents. A placebo-controlled study. Acta Derm Venereol. 1998;78(1):60–62.
33.
VenderRB. Alternative treatment for Atopic Dermatitis: a selective review. Skin Therapy Lett. 2002;7(2):1–4.
34.
SheehanMPRustinMHAthertonDJ. Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet. 1992;340(8810):13–17.
35.
Giordano-LabadieFSchwarzeHPBazexJ. Allergic contact dermatitis from camomile used in phytotherapy. Contact Dermatitis. 2000;42(4):247.
36.
HigakiSMorimatsuSMorohashiM. Susceptibility of Propionibacterium acnes, Staphylococcus aureus and Staphylococcus epidermidis to 10 Kampo formulations. J Int Med Res. 1997;25(6):318–324.
HanifinJMChanSCChengJB. Type 4 phosphodiesterase inhibitors have clinical and In vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol. 1996;107(1):51–56.
39.
RamosC. CE Lecture on Atopic Dermatitis.
40.
GimenezJC. Atopic dermatits a review article. Alergol Immunol Clin. 2000;15(1):279–295.
41.
BleehenSSChuACHamannI. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment andonce-daily vehicle cream application versus twice-daily treatment. Br J Dermatol. 1995;133(4):592–597.
42.
SearsHWBaileyJWYeadonA. Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis. Clin Ther. 1997;19(4):710–719.
AshcroftDMDimmockPGarsideR. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of Atopic Dermatitis: meta-analysis of randomized controlled trials. BMJ. 2005;7(8):330–516.
45.
WeinbergJM. Formulary review of therapeutic alternatives for atopic dermatitis: focus on pimecrolimus. J Manag Care Pharm. 2005;11(1):56–64.
46.
PaulCCorkMRossiAB. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics. 2006;117(1):e118–e128.
47.
BergerTGDuvicMVan VoorheesAS. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol. 2006;54(5):818–823.
48.
FonacierLSpergelJCharlesworthEN. Report of the topical calcineurin inhibitor task force of the American College of allergy, asthma and immunology and the american academy of allergy, asthma and immunology. J Allergy Clin Immunol. 2005;115(6):1249–1253.
49.
AbramowiczM. Drugs for allergic disorders. Treatment Guidelines. Med Lett. 2007;5(60):71–80.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
